Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Novo Nordisk submits application to regulatory authorities to include LEADER data in Victoza® label | |||||||||||||||||||||||||||||
By: Nasdaq / GlobeNewswire - 25 Oct 2016 | Back to overview list |
||||||||||||||||||||||||||||
Bagsværd, Denmark, 25 October 2016 - Novo Nordisk today announced the submission of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) and a Type II Variation application to the European Medicines Agency (EMA) for including data from the LEADER cardiovascular outcomes trial in the product information of Victoza ® (liraglutide). In the LEADER trial, Victoza ® statistically significantly reduced the risk of cardiovascular death, non-fatal myocardial infarction (heart attack) and non-fatal stroke by 13% versus placebo, when added to standard of care. The overall risk reduction was derived from a statistically significant 22% reduction in cardiovascular death with Victoza ® treatment versus placebo and non-significant reductions in non-fatal myocardial infarction and non-fatal stroke. The safety profile of Victoza ® in LEADER was generally consistent with previous liraglutide clinical trials. "Reducing the risk of cardiovascular death in people with type 2 diabetes remains a significant unmet need and it is encouraging that we now have the opportunity to help address this challenge," said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. " Victoza ® is the first GLP-1 receptor agonist to show cardiovascular risk reduction in adults with type 2 diabetes at high cardiovascular risk and we look forward to working with the regulatory authorities as they review the data from the LEADER trial."
About the LEADER trial
LEADER was initiated in September 2010 and randomised 9,340 people with type 2 diabetes from 32 countries. The primary endpoint was the first occurrence of a composite cardiovascular outcome comprising cardiovascular death, non-fatal myocardial infarction or non-fatal stroke.
About Victoza
®
Victoza ® was approved in the EU in 2009 and is commercially available in more than 85 countries, treating more than 1 million people with type 2 diabetes globally. In Europe, Victoza ® is indicated for the treatment of adults with type 2 diabetes to achieve glycaemic control as monotherapy, when metformin is considered inappropriate, and in combination with oral glucose-lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control. In the US, Victoza ® was approved in 2010 as an adjunct to diet and exercise to improve blood glucose control in adults with type 2 diabetes. Further information
Company announcement No 72 / 2016
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Novo Nordisk A/S via GlobeNewswire
HUG#2050994
|
|||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||
Copyright 2016 Nasdaq / GlobeNewswire | Back to overview list |